Objective: Up to 40% of patients with schizophrenic psychoses have symptoms that are
resistant to monotherapy with antipsychotic drugs. In consequence, combinations of drugs …

The role of olanzapine in treatment-resistant schizophrenia is still unresolved. This article
presents an open-label, prospective, 14-week trial with olanzapine in patients with …

Coadministration of olanzapine, an atypical neuroleptic, with sulpiride, a selective D 2
antagonist, is suggested as an efficient strategy for treating patients with resistant …

Background: When patients with schizophrenia fail to respond to an atypical antipsychotic,
they are sometimes switched to another atypical compound. However, the benefits of such a …

To date there is no common or adequate therapeutic strategy for treatment of refractory
schizophrenic patients. Increasing antipsychotics' doses in treatment-resistant schizophrenic …

Background: Clozapine is currently the treatment of choice for neuroleptic-resistant
schizophrenia. Olanzapine is a new antipsychotic drug that has shown efficacy against …

Objective: The aim of this study is to provide long-term data on the effectiveness and safety
of olanzapine in a group of patients with severe refractory schizophrenia. General Methods …

Several recent studies, albeit limited in sample number, design and generalizability, have
suggested that augmentation of atypical antipsychotic medication (such as clozapine and …

Introduction. Since a variety of comparisons between risperidone and olanzapine have
resulted in diverse outcomes, so safety and efficacy of them were compared again in a new …

Background: Conventional antipsychotics although effective in treating acute psychotic and
behavioural symptoms are subject to certain limitations due to the high incidence of side …